Key statistics
On Friday, Fate Therapeutics Inc (F6T:FRA) closed at 2.34, 26.45% above the 52 week low of 1.85 set on Nov 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.34 |
---|---|
High | 2.34 |
Low | 2.34 |
Bid | 2.24 |
Offer | 2.27 |
Previous close | 2.57 |
Average volume | 1.48k |
---|---|
Shares outstanding | 113.88m |
Free float | 111.40m |
P/E (TTM) | -- |
Market cap | 275.58m USD |
EPS (TTM) | -1.71 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 07:19 GMT.
More ▼
Announcements
- Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
- Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
- Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
- Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
- Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
- Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
- Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
More ▼